Prospective, randomized, double-blind, controlled clinical trial to compare the effect of 9 months of treatment with dapagliflozin vs. placebo on anthracycline-induced cardiotoxicity in patients with breast cancer.
Female
Over 18 years old
Breast cancer
Chemotherapy as treatment planning and programmed cumulative dose equivalent to 240 mg/m2 of doxorubicin.
Contraindications for performing CMR exams, such as patients with pacemakers or cardiac defibrillators of any type, metal clips for cerebral aneurysms, cochlear implants, and ventriculoperitoneal bypass valves.
Inability to perform CMR due to claustrophobia.
Renal failure with a glomerular filtration rate < 30 ml/min/1.73 m2.
Previous history of myocardial infarction, congestive heart failure, or myocardial revascularization, whether percutaneous or surgical.